background

MyNovocure® support program

Page title image

The MyNovocure program ensures patients receive optimal care during treatment with Optune Lua

MyNovocure logo

Offering a comprehensive suite of services designed for support throughout treatment

Patient speaking on the phone with icons representing MyNovocure's 24/7 patient support service.

Prescribing Optune Lua

Discover how MyNovocure can help guide your practice and patients through each step of the Optune Lua journey

MyNovocure provides 24/7 assistance for your practice and patients throughout the treatment journey

 

For patient assistance, insurance questions, technical support, physician information, and general inquiries, please contact MyNovocure support through either method below.

Icon of a telephone for contacting Optune Lua support.

1-855-281-9301 

(toll-free)

Novocure is NOT permitted to provide medical advice to patients. All patients with medical questions will be referred back to their healthcare provider.

Assisting you and your patients from prescription to treatment

MyNovocure has a dedicated team of experts who are ready to provide live 24/7 support for your patients and your practice throughout treatment on Optune Lua

Meet the MyNovocure Team

Icon of a person and a prescription pad representing an Intake Coordinator.

Intake Coordinator

  • Manages prescription process and supportive documentation
Icon of a person and money representing a Financial Coordinator.

Financial Coordinator

  • Works with your patient's insurance plan and identifies resources and programs to minimize the cost for Optune Lua
  • Completes welcome calls to prepare patients for Optune Lua treatment initiation
Icon of a person and telephone representing a Care Coordinator.

Care Coordinator

  • Addresses patient's questions regarding lifestyle adjustments and any other concerns 24/7
Icon of a person and a serving hand representing a device support spacialist.

Device Support Specialist

  • Delivers the device to the patient’s home or practice, providing in-person training 
  • Notifies the practice once the patient initiates the device and provides monthly usage data
  • Checks in regularly with the patient to discuss usage and provide support during their journey
Icon of a nurse and whiteboard representing a Nurse Educator.

Nurse Educator

  • Executes in-service programs (in or out of office) for med/onc nurses
  • Supports HCPs and patients with the Understanding Optune Lua: Patient Education Program, providing additional information about Optune Lua to patients and HCPs
Icon of 3 people and one raising their hand exemplifying a territory manager.

Territory Manager

  • Acts as a key point of contact and offers educational support and materials for staying updated on the latest Optune Lua developments
Patient performing yoga while wearing the Optune Lua device, illustrating MyNovocure support services.

Actor portrayal.

Download helpful resources for your practice and patients

Review these resources

Novocure is NOT permitted to provide medical advice to patients. All patients with medical questions will be referred back to their healthcare provider.

EMR, electronic medical record; HCP, healthcare professional.

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Important Safety Information 

Contraindications 

Do not use Optune Lua® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device. 

 

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions 

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure® (the device manufacturer). 

 

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established. 

 

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia. 

 

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer. 

 

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

 

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen. 

 


Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Novocure Websites

This website is intended for US healthcare professionals seeking information on Optune Lua.

 

 

 

 


External links

OptuneGioHCP.com
OptuneLuaHCP.com/MPM
Novocuretrials.com


Novocure logo

©2025 Novocure GmbH. All Rights Reserved. 

Optune Lua, MyNovocure, MyLink, and Novocure are trademarks of Novocure GmbH.

US-OPL-00433 v1.0 june 2025